CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-10 | OYLER JOHN Chief Executive Officer | Option exercise · Share Option (Right to Buy) 10b5-1 | −152,074 | 1,895,426 | ||
| 2026-07-08 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +202 | $194.47 | $39K | 202 |
| 2026-07-08 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +266 | $213.32 | $57K | 468 |
| 2026-07-08 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +196 | $159.03 | $31K | 664 |
| 2026-07-08 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −664 | $302.46 | $201K | 0 |
| 2026-07-08 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −2,626 | 17,238 | ||
| 2026-07-08 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −3,458 | 79,768 | ||
| 2026-07-08 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −2,548 | 105,300 | ||
| 2026-06-23 | Wang Lai President, Global Head of R&D | Sale | −1,068 | $276.74 | $296K | 0 |
| 2026-06-23 | Wu Xiaobin President and COO | Sale | −1,292 | $276.26 | $357K | 0 |
| 2026-06-23 | OYLER JOHN Chief Executive Officer | Sale | −1,800 | $273.30 | $492K | 1,610 |
| 2026-06-23 | OYLER JOHN Chief Executive Officer | Sale | −1,290 | $274.12 | $354K | 320 |
| 2026-06-23 | OYLER JOHN Chief Executive Officer | Sale | −320 | $275.10 | $88K | 0 |
| 2026-06-16 | Lee Chan Henry SVP, General Counsel | Sale | −590 | $265.98 | $157K | 0 |
| 2026-06-16 | Wang Lai President, Global Head of R&D | Sale | −1,169 | $265.39 | $310K | 0 |
| 2026-06-16 | Wu Xiaobin President and COO | Sale | −1,357 | $266.76 | $362K | 0 |
| 2026-06-16 | OYLER JOHN Chief Executive Officer | Sale | −1,650 | $264.87 | $437K | 2,043 |
| 2026-06-16 | OYLER JOHN Chief Executive Officer | Sale | −1,710 | $265.99 | $455K | 333 |
| 2026-06-16 | OYLER JOHN Chief Executive Officer | Sale | −333 | $266.69 | $89K | 0 |
| 2026-06-11 | Mooney Elizabeth Fisher Director | Grant or award | +18,980 | 18,980 |
Page 10 of 71 · 1,406 trades